- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Dr. Smith's Diaper Rash Ointment
- ROUNDTABLE: Pharmacy’s future in sync with technology
- Economic analysis: Prescription-only status for PSE would drive up physician visits, healthcare costs
- EXPERT BLOG: Provider status for pharmacists — one way or another
WASHINGTON —The industry-supported Combat Methamphetamine Enhancement Act, H.R. 2923, passed muster at the House Committee on Energy and Commerce last month. The bipartisan bill now has moved before the full U.S. House of Representatives for approval.
The bill would require retailers to self-certify with the Drug Enforcement Administration that they comply with current safeguards. These safeguards prevent single customers from purchasing suspiciously large quantities of certain products, require distributors of these products to sell only to retailers who are registered with the DEA and establish civil fines for those who fail to comply with the regulations.
“Our membership has long supported both local and national efforts to combat methamphetamine abuse and production,” Steve Anderson, president and CEO of the National Association of Chain Drug Stores, wrote in a July 28 letter to the Committee on Energy and Commerce. “In fact, even before the introduction of state and federal legislation, the majority of the chain pharmacies took voluntary, proactive steps to reduce the theft and illegitimate use of products containing pseudoephedrine…. Moreover, our members have worked closely with DEA and state and local law enforcement officials since 1995 to stem the tide of methamphetamine production in communities across the United States.”
In addition to NACDS, the bill also is supported by the Community Anti-Drug Coalitions of America, the National Fraternal Order of Police, the Healthcare Distribution Management Association and the Consumer Healthcare Products Association.